3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
1
Conditions
Neuroendocrine Tumors
46
Pituitary Neoplasms
19
Neoplasms
14
Thyroid Neoplasms
13
Pheochromocytoma
13
Thyroid Carcinoma, Anaplastic
12
Thyroid Cancer, Papillary
12
Neoplasm Metastasis
12
Adrenocortical Carcinoma
11
Paraganglioma
9
Insulinoma
9
Carcinoid Tumor
9
Adrenal Gland Neoplasms
9
Somatostatinoma
8
Glucagonoma
8
Colorectal Neoplasms
8
Carcinoma, Renal Cell
8
Carcinoma, Islet Cell
8
Pancreatic Neoplasms
7
Gastrinoma
7
Carcinoma, Neuroendocrine
7
Breast Neoplasms
7
Melanoma
6
Head and Neck Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Adenoma, Islet Cell
6
Small Cell Lung Carcinoma
5
Multiple Endocrine Neoplasia Type 1
5
Lung Neoplasms
5
Gastro-enteropancreatic neuroendocrine tumor
5
Interventions
trifluridine tipiracil drug combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
High-grade Extra Pulmonary Neuroendocrine Cancer
×
Endocrine
×
Clear all
NCT04042714
2025-11-04
TAS-102 NEC
Baylor Research Institute
Phase 2
Terminated
14 enrolled